Pharmaceutical Technology14d
Baluretgene parvec by Ocugen for Leber Congenital Amaurosis (LCA): Likelihood of Approval
Baluretgene parvec is under clinical development by Ocugen and currently in Phase III for Leber Congenital Amaurosis (LCA). According to GlobalData, Phase III drugs for Leber Congenital Amaurosis (LCA ...
Pharmaceutical Technology15d
PR-15 by AdvanceCor for Coronary Artery Disease (CAD) (Ischemic Heart Disease): Likelihood of Approval
PR-15 (revacept, GPVI-Fc) is under development for the treatment of symptomatic carotid stenosis, coronary artery disease, transient-ischemic attacks, Amaurosis fugax or stroke and peripheral arterial ...
Medscape2mon
Recurrent Stroke Risk Is High After a Single Cerebrovascular Event in Patients With Symptomatic 50–99% Carotid Stenosis
Patients with stroke or retinal artery occlusion as presenting event were more often clinically stable than patients with TIA or amaurosis fugax as presenting event (p = 0.004, chi-squared test ...